FARADAY PHARMACEUTICALS
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
FARADAY PHARMACEUTICALS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2014-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.faradaypharma.com
Total Employee:
1+
Status:
Active
Contact:
206-452-8700
Email Addresses:
[email protected]
Total Funding:
88 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Organization Schema Office 365 Mail JsDelivr
Current Employees Featured
Founder
Investors List
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Faraday Pharmaceuticals
Polaris Partners
Polaris Partners investment in Series B - Faraday Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Faraday Pharmaceuticals
Washington Research Foundation
Washington Research Foundation investment in Series A - Faraday Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Faraday Pharmaceuticals
Washington Research Foundation
Washington Research Foundation investment in Series A - Faraday Pharmaceuticals
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series A - Faraday Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Faraday Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Faraday Pharmaceuticals
Polaris Partners
Polaris Partners investment in Series A - Faraday Pharmaceuticals
Official Site Inspections
http://www.faradaypharma.com Semrush global rank: 5.11 M Semrush visits lastest month: 1.6 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Faraday Pharmaceuticals"
Leadership - Faraday Pharmaceuticals
Stephen A. Hill, BM BCh MA FRCS Faraday Pharmaceuticals. Steven Gillis, Ph.D. ARCH Venture Partners. Lawrence Gozlan Scientia CapitalSee details»
Our Story — Faraday Pharmaceuticals
Faraday’s innovative approach to medicine stems from our beginnings. We are a clinical-stage biopharmaceutical company founded by Dr. Mark Roth of the Fred Hutchinson Cancer Center in Seattle and backed by an investor group led by …See details»
Faraday Pharmaceuticals - Crunchbase Company …
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements …See details»
Org Chart Faraday Pharmaceuticals - The Official Board
The organizational chart of Faraday Pharmaceuticals displays its 11 main executives including Stephen Hill, Shannon Wilson and Brian BlackmanSee details»
Faraday Pharmaceuticals, Inc. | LinkedIn
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301 https://lnkd.in/g-Xm2u3n - 2,300 patients in trial enrolled ahead of schedule - 12 ...See details»
Faraday Pharmaceuticals CEO and Key Executive Team - Craft
Faraday Pharmaceuticals's Director is Terry McGuire. Other executives include Stephen A. Hill, Chief Executive Officer, Director; Tressa Randall, Vice President Regulatory Affairs and 4 …See details»
Faraday Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Faraday Pharmaceuticals, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Faraday Pharmaceuticals, Inc. Information - RocketReach
Faradaypharma.com; 1 408355XXXX; View Similar People. Related Companies RareCyte, Inc. 78 $3m InBios International, Inc. 80 $14.3m Xealth. 83 $8m Chinook Therapeutics, Inc. 255 $2m …See details»
Faraday Pharmaceuticals - VentureRadar
Website: http://faradaypharma.com/ Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents.See details»
Overview, News & Similar companies - ZoomInfo.com
Dec 26, 2021 Faraday Pharmaceuticals contact info: Phone number: (206) 452-8700 Website: www.faradaypharma.com What does Faraday Pharmaceuticals do? Faraday …See details»
Faraday Pharmaceuticals - Craft
Faraday Pharmaceuticals has 5 employees at their 1 location and $88 m in total funding,. See insights on Faraday Pharmaceuticals including office locations, competitors, revenue, …See details»
Faraday Pharmaceuticals Announces the Appointment of Dr.
Solvay was acquired by Abbott Labs in 2010. From 1999 to 2008, Dr. Hill served as President and CEO of ArQule where he successfully implemented the company’s transition from a chemistry …See details»
Faraday Pharmaceuticals, Inc. | European Clinical Trials Information ...
In 2016, the company merged with another biotech firm, Mitobridge, to create a stronger and more diversified organization. This merger brought together two complementary sets of expertise …See details»
Faraday Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. 1616 Eastlake Avenue East Suite 560. Seattle, Washington, 98102, United States. 206-492-5310See details»
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase …
Oct 14, 2021 Expands the potential therapeutic use of FDY-5301SEATTLE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a biopharmaceutical company …See details»
PR — Faraday Pharmaceuticals
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301. Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company …See details»
Faraday Pharmaceuticals Announces Agreement with FDA on …
Jan 4, 2024 Faraday Pharmaceuticals. Interim analysis estimated to occur in late Q2 2024 and will be based on at least 50% of anticipated primary outcomes. Pivotal Phase 3 trial continues …See details»
Careers — Faraday Pharmaceuticals
Life at Faraday We’re working to provide patients with longer, healthier lives by making critical illness less critical. We’ve assembled an experienced, collaborative and deeply dedicated …See details»
Our Science — Faraday Pharmaceuticals
FDY-5301’s unique properties are well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models FDY-5301, a formulation of sodium iodide, reduced tissue damage, …See details»